Clinical Trials Logo

Tumors clinical trials

View clinical trials related to Tumors.

Filter by:

NCT ID: NCT00129337 Completed - Tumors Clinical Trials

Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies

Start date: June 2005
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety of bavituximab when administered via a vein, and to examine how bavituximab behaves in the body - how quickly it is taken up by the body and how long it stays there. The effect of bavituximab on tumor responses will also be examined.

NCT ID: NCT00129207 Completed - Tumors Clinical Trials

Ketoconazole Administration: How it is Affected by the Body and Broken Down and How it Acts on the Body When Used With Velcade

Start date: n/a
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate how ketoconazole (Nizoral) affects the pharmacokinetics (how the study drug is affected by the body and broken down) and pharmacodynamics (how the study drug acts on the body) of the active ingredient in the study drug Velcade (bortezomib).

NCT ID: NCT00127829 Completed - Tumors Clinical Trials

Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic

AGUS
Start date: July 2005
Phase: Phase 1
Study type: Interventional

This study will determine the safety profile and maximum tolerated dose (MTD) of orally administered gefitinib on a weekly and twice weekly schedule.

NCT ID: NCT00127127 Completed - Tumors Clinical Trials

A Study of Vorinostat in Patients With Solid Tumors (MK-0683-029)

Start date: June 10, 2005
Phase: Phase 1
Study type: Interventional

The primary purpose of this trial is to determine the maximum tolerated dose (MTD), or the maximum acceptable dose (MAD) and evaluate the dose limiting toxicity (DLT) of oral suberoylanilide hydroxamic acid in participants with solid tumors.

NCT ID: NCT00125411 Terminated - Tumors Clinical Trials

Study of Satraplatin (JM-216) in Combination With Docetaxel

Start date: March 2007
Phase: Phase 1
Study type: Interventional

This is a single center, open-label, non-randomized, Phase I dose finding study of the investigational, oral cytotoxic drug, satraplatin (JM-216), in combination with docetaxel in patients with advanced solid tumors for whom curative therapy is not available. Please refer to the Eligibility Criteria below for key inclusion and exclusion criteria. PURPOSE: The purpose of this trial is to determine a tolerable dose and schedule for the combination of satraplatin and docetaxel when given to patients with advanced solid tumors. WHAT IS SATRAPLATIN: Satraplatin is an oral, investigational anticancer drug that is a member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given orally.

NCT ID: NCT00113113 Completed - Tumors Clinical Trials

Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction

Start date: August 2001
Phase: Phase 1
Study type: Interventional

Cancer patients with liver or renal dysfunction will be treated with rubitecan capsules to define the maximum tolerated dose and the dose-limiting toxicity in this patient population, and to perform pharmacokinetic studies of rubitecan in this patient population.

NCT ID: NCT00105170 Terminated - Tumors Clinical Trials

Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid Tumors

Start date: January 2005
Phase: Phase 1
Study type: Interventional

This is a Phase I, open-label, dose-escalation study on subjects with advanced solid tumors. This is the first study of hCBE-11 in humans and is designed to determine the safety and how well patients tolerate this investigational drug. The study duration is two years with treatment visits occurring weekly for either 4 or 8 weeks, follow-up for 8 weeks and long-term follow-up contact every 3 months thereafter.

NCT ID: NCT00102830 Completed - Tumors Clinical Trials

Study Evaluating AMG 386 in Adult Patients With Advanced Solid Tumors

Start date: n/a
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety, tolerability and pharmacokinetic (PK) profile of AMG 386 after intravenous administration in adult subjects with advanced solid tumors.

NCT ID: NCT00093873 Completed - Tumors Clinical Trials

Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors

Start date: July 2003
Phase: Phase 1
Study type: Interventional

This study will determine the safety and pharmacokinetics of AMG 706 in subjects with advanced solid tumors.

NCT ID: NCT00091806 Completed - Solid Tumors Clinical Trials

Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors

Start date: August 2004
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and pharmacokinetics of two dose schedules of panitumumab in subjects with advanced solid tumors.